Summary We examined for transforming growth factora (TGFa) Human transforming growth factora (TGFa), a mitogenic polypeptide, is composed of 50 amino acids. There is a 42% homology with human epidermal growth factor (EGF) (Derynck et al., 1984; Marquardt et al., 1984; Lee et al., 1985) . TGFa binds to the EGF receptor (EGFR) and the binding affinity is equal to that of EGF (Lynsley et al., 1985) . It is generally accepted that the actions of TGFa are mediated through EGFR. After binding to EGFR, TGFx activates the tyrosine kinase subunit and autophosphorylation of the receptor occurs (Reynolds et al., 1981) .
in adenocarcinomatous lesions of the lung tissues excised from 138 patients, with use of the avidin-biotin-peroxidase complex (ABC) method. TGFa was present in the cytoplasm of the adenocarcinoma. Our objective was to determine if TGFa could serve as a prognostic parameter. We divided 138 patients into two groups according to the concentration of TGFa. Ninety-two patients had a high concentration of TGFa, in over 75% of the tumour cells, while 46 had a low concentration, that is in less than 75% of the cells. The 5-year survival rates of patients with high TGFa and low TGFa were 39% and 64%, respectively (P <0.05). Our data suggest that evidence of a high immunoreactivity of TGFa can serve as a prognostic parameter in adenocarcinoma of the lung.
Human transforming growth factora (TGFa), a mitogenic polypeptide, is composed of 50 amino acids. There is a 42% homology with human epidermal growth factor (EGF) (Derynck et al., 1984; Marquardt et al., 1984; Lee et al., 1985) . TGFa binds to the EGF receptor (EGFR) and the binding affinity is equal to that of EGF (Lynsley et al., 1985) . It is generally accepted that the actions of TGFa are mediated through EGFR. After binding to EGFR, TGFx activates the tyrosine kinase subunit and autophosphorylation of the receptor occurs (Reynolds et al., 1981) .
TGF-like factor has been noted in conditioned media, from a variety of human tumour cell lines as well as from cell extracts (Salmon et al., 1984; Hamburger et al., 1985; Smith et al., 1987; Betsholtz et al., 1987) . TGFa has also been extracted from newly excised human malignant neoplasms (Nickell et al., 1983) and is also present in urine (Sherwin et al., 1983) or effusions (Hanauske et al., 1988) (Kaplan et al., 1958) . Comparisons among survival rates were made by the log rank test (Peto et al., 1977) . Multivariate analysis was performed using Cox's proportional hazards regression model (Cox, 1972) . Computations were carried out using the statistical package, BMDP (Dixon, 1985) 1L and 2L, on an IBM system 4381 computer. The difference was considered to be significant when the P value was less than 0.05.
Results
Immunoperoxidase reactivity for TGFa was evident in the cytoplasm of the cancer cells (Figure la,b) .~~~~. The 5-year survival rates of patients with +, + + and + + + were 60%, 70% and 39%, respectively. The extent of both + and + + was designed low TGFa, and that of + + + was high TGFa. The 5-year survival rates of patients separated by immunoreactivity of TGFO are shown in Table  I . In case of N2 and stage IIIA, there were statistically significant differences in the survival rates of patients with high TGFax and low TGFa (P < 0.05). As shown in Figure 2 , the 5-year survival rates of overall patients with high TGFax and low TGFa were 39% and 64%, respectively (P <0.05).
To compare the prognostic significance of variables, a multivariate analysis were performed. Significant variables for survival were recognised in the factors of TGFa, N, and stage (P <0.05) (Table II) . 
Discussion
TGFx plays a role in modulating cellular proliferation and differentiation (Bennet et al., 1989) . This growth factor is secreted from transformed and from non-transformed cells. Thus TGFa is involved in autocrine and/or paracrine stimulation in epithelial proliferation and repair, without an associated malignant transformation Madtes et al., 1988) . (Macias et al., 1987; Derynck et al., 1987) . In a malignant tumour, the coexpression of mRNA encoding both TGFa and EGFR is higher than that in cases of inflammatory disease (Bennet et al., 1989) . Malignant cells originating from pancreatic cancer overexpressing EGFR, synthesised in vitro a considerable amount of mRNA encoding TGFa (Smith et al., 1987) . The presence of both TGFa and EGFR in the same tissue suggests the involvement of autocrine mechanisms, that is, its own growth factor is secreted.
TGF-like factor was detected in lung cancer cell lines (Hamburger et al., 1985; Betsholtz et al., 1987) . We obtained immunohistochemical evidence of TGRa in tissues from human lung adenocarcinoma. Intense staining for TGFa in more than 75% of the tumour cells was detected in 67% of the lesions and the amount of TGFa correlated well with the prognosis of the advanced stage, especially in those with N2 stage of the disease.
EGF which is structurally related to TGFa proved to be prognostic parameter in cases of gastric cancer (Tahara et al., 1986) . The immunoreactivity of EGF in early gastric carcinoma was not evident (Japanese Research Society for Gastric Cancer, 1981), while EGF was detected 21% of advanced gastric carcinomas and 33% of the scirrhous carcinomas. Thus, the co-expression of both TGFa and EGFR in lung cancer has to be examined using immunohistochemical assays. Comparative studies should clarify the potential of cancer cells to produce and respond to their own growth factor, such as tumour invasiveness, lymphatic permeation or vascular metastasis.
The prognosis of patients with advanced lung cancer is poor; 15% of the patients in stage IIIA survive for 5 years (Mountain, 1986) and 14% with an adenocarcinoma and N2 disease survive for 5 years (Mountain, 1985) . All our patients with an advanced lung cancer and high concentrations of TGFa had a poor prognosis.
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